68Ga DOTA-Exendin PET/CT for Detection of Insulinoma in a Patient With Persistent Hyperinsulinemic Hypoglycemia. (August 2018)

• Record Type: Journal Article
• Authors: Parihar, Ashwin Singh; Vadi, Shelvin Kumar; Kumar, Rajender; Mittal, Bhagwant Rai; Singh, Harmandeep; Bal, Amanjit; Walia, Rama; Shukla, Jaya; Sinha, Saroj Kumar
• Is Part Of: Clinical nuclear medicine. Volume 43:Number 8(2018)
• Publication Date: 2018-08
• Subjects: exendin -- PET/CT -- insulinoma -- DOPA -- neuroendocrine tumors; Nuclear medicine -- Periodicals; Radioisotope scanning -- Periodicals; Nuclear Medicine -- Periodicals; 616.07575
• DOI: 10.1097/RLU.0000000000002155
• Languages: English
• ISSNs: 0363-9762

Abstract

Abstract : Abstract: Insulinomas are the most common functioning pancreatic neuroendocrine tumors and the leading cause of persistent hypoglycemia with hyperinsulinemia in adults. Glucagon-like-peptide-1 (GLP) receptor analogs are the latest agents being used in the detection of insulinomas, with initial reports suggesting high sensitivity due to universal GLP1 receptor expression on these tumors. PET/CT imaging in this patient using 68 Ga DOTA-Exendin, a GLP receptor analog, proved useful for accurate localization of the culprit lesion, aiding in the definitive management of the patient.